DE60239284D1 - Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung - Google Patents

Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung

Info

Publication number
DE60239284D1
DE60239284D1 DE60239284T DE60239284T DE60239284D1 DE 60239284 D1 DE60239284 D1 DE 60239284D1 DE 60239284 T DE60239284 T DE 60239284T DE 60239284 T DE60239284 T DE 60239284T DE 60239284 D1 DE60239284 D1 DE 60239284D1
Authority
DE
Germany
Prior art keywords
tetrahydropyridyl
alkyl
azotated
tnf effect
alkyl heterocycles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239284T
Other languages
German (de)
English (en)
Inventor
Marco Baroni
Bernard Bourrie
Pierre Casellas
Letizia Puleo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE60239284D1 publication Critical patent/DE60239284D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
DE60239284T 2001-11-19 2002-11-18 Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung Expired - Lifetime DE60239284D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0114897A FR2832405B1 (fr) 2001-11-19 2001-11-19 Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
PCT/FR2002/003929 WO2003044010A1 (fr) 2001-11-19 2002-11-18 Tetrahydropyridyl-alkyl-heterocycles azotes avec une activity du tnf______

Publications (1)

Publication Number Publication Date
DE60239284D1 true DE60239284D1 (de) 2011-04-07

Family

ID=8869506

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239284T Expired - Lifetime DE60239284D1 (de) 2001-11-19 2002-11-18 Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung

Country Status (12)

Country Link
US (1) US7211578B2 (https=)
EP (1) EP1448550B1 (https=)
JP (1) JP4603794B2 (https=)
AT (1) ATE499359T1 (https=)
AU (1) AU2002356244B2 (https=)
CA (1) CA2464721C (https=)
DE (1) DE60239284D1 (https=)
FR (1) FR2832405B1 (https=)
HU (1) HUP0402229A3 (https=)
MX (1) MXPA04004760A (https=)
PL (1) PL208647B1 (https=)
WO (1) WO2003044010A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4885572A (https=) * 1972-02-17 1973-11-13
JPS49100090A (https=) * 1973-01-30 1974-09-20
JPS49100089A (https=) * 1973-01-30 1974-09-20
JPS5236B2 (https=) * 1973-03-28 1977-01-05
JPS5046669A (https=) * 1973-03-28 1975-04-25
DE19517851A1 (de) * 1995-05-16 1996-11-21 Hoechst Ag Organometallverbindung
FR2757160B1 (fr) 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
DZ2796A1 (fr) * 1998-05-21 2003-12-01 Smithkline Beecham Corp Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
HK1046532B (zh) * 1999-10-22 2005-03-18 Sanofi-Aventis 具有抑制tnf活性的苯基-和吡啶基-四氫吡啶
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
SI1283839T1 (https=) * 2000-05-26 2005-08-31 Schering Corp

Also Published As

Publication number Publication date
WO2003044010A1 (fr) 2003-05-30
FR2832405B1 (fr) 2004-12-10
US20050004132A1 (en) 2005-01-06
PL370832A1 (en) 2005-05-30
JP4603794B2 (ja) 2010-12-22
EP1448550A1 (fr) 2004-08-25
JP2005509678A (ja) 2005-04-14
PL208647B1 (pl) 2011-05-31
CA2464721C (en) 2011-03-08
AU2002356244A1 (en) 2003-06-10
FR2832405A1 (fr) 2003-05-23
ATE499359T1 (de) 2011-03-15
HUP0402229A2 (hu) 2005-02-28
EP1448550B1 (fr) 2011-02-23
HUP0402229A3 (en) 2009-07-28
AU2002356244B2 (en) 2008-07-24
US7211578B2 (en) 2007-05-01
MXPA04004760A (es) 2004-07-30
CA2464721A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
GR3030515T3 (en) Aroyl-piperidine derivatives
DK1382604T3 (da) Quinolinderivater med en azolylgruppe og quinazolinderivater
ATE219077T1 (de) Endothelin antagoniste
ATE211735T1 (de) 1-phenyl-pyrazolderivate und ihr verwendung als schädlingsbekämpfungsmittel
EP1535910A4 (en) CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORILATION OF THE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR
AR021533A1 (es) Derivados de 2,5-diazabiciclo[2.2.1]heptano, su preparacion y su aplicacion en terapeutica
ATE72436T1 (de) 2-(methyl(4-piperidinyl)>-1,2,3,4-tetrahydro-9h pyrido(3,4-b>indolderivate, ihre herstellung und therapeutische verwendung.
ATE161259T1 (de) Ampa antagonisten und behandlungsmethode
DK0677042T3 (da) Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler
GB8716971D0 (en) Therapeutic agents
DK1202954T3 (da) Nye aminobenzophenoner
DE60239284D1 (de) Azotierte tetrahydropyridyl-alkyl-heterozyklen mit tnf-wirkung
DE69228017D1 (de) Verwendung von 4-Amino-1-(2-Pyridyl)Piperidinen als 5-HT3-Agonisten zur Behandlung und Verhütung von serotoninergen Dysfunktionen
MXPA03011032A (es) Activadores de derivados de oxazol/tiazol del receptor hppar-alfa.
EP1031572A4 (en) PYRIDYLPYRROL DERIVATIVES
IL158641A0 (en) Process for preparing a thiazole ppar-ligand and polymorphs thereof
ES538756A0 (es) Procedimiento para preparar l-acilimidazolinonas
DK1023287T3 (da) Derivater af 3-oxo-(2H)-1,2,4-triazin som ligander for 5HT1a-receptorer
CY1108404T1 (el) Βητα-λακταμες για θεραπεια διαταραχων του κνς
NO950574L (no) Akronycinanaloger
EP1020426A4 (en) AMINE DERIVATIVES AND THEIR PRODUCTION PROCESS
PL338944A1 (en) Method of obtaining n-[5-(diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-n-methylmethanesulphonamide
FR2840304A1 (fr) Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique
ECSP951529A (es) Compuestos farmaceuticos
DE69701770D1 (de) Enolether und ihre Verwendung als Fungizide